Denali Therapeutics
DNLI
DNLI
189 hedge funds and large institutions have $2.8B invested in Denali Therapeutics in 2022 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 67 increasing their positions, 69 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
26% less capital invested
Capital invested by funds: $3.8B → $2.8B (-$998M)
53% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 40
55% less call options, than puts
Call options by funds: $818K | Put options by funds: $1.8M
Holders
189
Holding in Top 10
2
Calls
$818K
Puts
$1.8M
Top Buyers
| 1 | +$25.7M | |
| 2 | +$21.9M | |
| 3 | +$21.8M | |
| 4 |
Morgan Stanley
New York
|
+$13.5M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.26M |
Top Sellers
| 1 | -$11M | |
| 2 | -$10M | |
| 3 | -$9.04M | |
| 4 |
CM
Crestline Management
Fort Worth,
Texas
|
-$7.86M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$7.44M |